10 Best Cancer Stocks To Buy Now

6. Danaher Corporation (NYSE:DHR)

Hedge Fund Holdings: 83 

Danaher Corporation (NYSE:DHR) is a global science and technology innovator focused on improving human health through its Biotechnology, Life Sciences, and Diagnostics segments. The company provides bioprocessing technologies, lab equipment, and diagnostic tools, serving pharmaceutical companies, research institutions, and hospitals worldwide. In cancer research and treatment, Danaher stands out for its comprehensive approach, offering rapid PCR testing through Cepheid, genomic tools via IDT, bioprocessing technologies from Pall and Cytiva, and advanced pathology solutions from Leica Microsystems. These capabilities support cancer diagnostics, research, and therapy development across the entire workflow.

In Q2 2024, Danaher Corporation (NYSE:DHR) reported $5.74 billion in sales, surpassing expectations of $5.59 billion despite a 3% year-over-year decline. On an organic basis, revenue dropped 3.5%, but the company’s bioprocessing division showed recovery, with orders increasing sequentially. A key catalyst was Danaher’s Cepheid division, which exceeded sales expectations by $100 million, signaling resilience in its core businesses.

In Q2 2024, there were 83 hedge fund holders in the company with Fisher Asset Management being the largest holder with 4,436,341 worth $1,108,420,324. Danaher Corporation (NYSE:DHR) receives a moderate buy rating from 14 Wall Street analysts. The average price target is $280.93, with a high of $310.00 and a low of $250.00, representing a 5.59% increase from the last price of $266.06.